Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-Targeted therapy in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Thymic Epithelial Tumors

Résumé fourni par la source

The European Society for Medical Oncology (ESMO) Congress 2024 presented pivotal new data across various trials that continue to explore the nuances of immunotherapy (ICI) in non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In early-stage lung cancer, additional data was presented for immune-checkpoint-inhibitor therapy in the perioperative setting, aiming to deepen the knowledge of potential predictive markers. An update from the ADRIATIC study on limited-stage SCLC provided new insights into various subgroups, including the impact of different aspects of radiation therapy and the choice of platinum doublet chemotherapy. In the context of palliative treatment of NSCLC several studies focused on optimizing first-line therapy, e.g. by incorporating anti-TIGIT or LAG-3 antibodies. Additionally, the issue of targeting resistance pathways in patients with advanced NSCLC was addressed. Deescalation of therapy was the aim of low-dose versus standard-dose Pembrolizumab in advanced NSCLC. Preliminary data in thymic epithelial tumors (TET) and immune-checkpoint-inhibitor (ICI) therapy in combination with Lenvatinib were presented in the PECATI trial.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.